Parcion Private Wealth LLC purchased a new stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 5,024 shares of the biopharmaceutical company’s stock, valued at approximately $260,000.
Other large investors have also made changes to their positions in the company. ESL Trust Services LLC purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at about $27,000. ORG Wealth Partners LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter valued at about $34,000. LGT Financial Advisors LLC increased its holdings in Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares in the last quarter. Redmont Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 1st quarter valued at about $47,000. Finally, MFA Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb during the 2nd quarter valued at about $39,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Stock Down 1.9 %
Shares of NYSE:BMY opened at $51.92 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86. The company has a fifty day simple moving average of $50.75 and a 200 day simple moving average of $46.41. The firm has a market cap of $105.25 billion, a PE ratio of -16.75, a price-to-earnings-growth ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $55.29.
Bristol-Myers Squibb Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.62%. Bristol-Myers Squibb’s payout ratio is -77.42%.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on BMY. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a report on Tuesday, July 23rd. Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Barclays raised their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target on the stock. Finally, StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $53.31.
Read Our Latest Research Report on BMY
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Featured Stories
- Five stocks we like better than Bristol-Myers Squibb
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Grocery Stocks That Are Proving They Are Still Essential
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.